EUVIMEDEUVIMED entdecken
EUVIMED · CrossrefZeitschrift

Blood Cancer Discovery

ISSN 2643-3230 · American Association for Cancer Research (AACR)

Neueste Artikel

  1. Preclinical characterization of the potent and selective MALT1 inhibitor safimaltib in B-cell lymphoma models

    Ulrike Philippar, Lorena Fontan, Min Xia, Nele Vloemans, Mariette Bekkers, Marcello Gaudiano, Onyi Irrechukwu, Diede van den Biggelaar, Tatiana Perova, Irene Guimerans-Lorenzo, Katarzyna Wnuk-Lipinska, Ivo Cornelissen, Marjolein van Heerden, Bas-Jan van der Leede, Katie Amssoms, Rui Xu, Joanna Grant, Emanuele Trella, Yann Abraham, Kristof Kimpe, Bart Medaer, Anthony Greway, Jan Snoeys, Frank Jacobs, Maxwell D. Cummings, Weimei Sun, Jan Willem. Thuring, Tongfei Wu, Stan Gaj, Bie Verbist, Peter J. Connolly, Nigel Austin, Sriram Balasubramanian, Jacqueline Kinyamu-Akunda, Kathryn Packman, James P. Edwards, Yusri Elsayed, Nele Fourneau, Franck Morschhauser, John F. Gerecitano

    Erschienen: 2026-11-09DOI: 10.1158/2643-3230.bcd-26-0182

  2. RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR T–Resistant Large B-cell Lymphomas

    Austin D. Newsam, Bachisio Ziccheddu, Abdessamad A. Youssfi, Venu Venkatarame Gowda Saralamma, Santiago Foos-Russ, Daniel E. Tsai, Isaiah Sheffield-Veney, Adithi Jeevan, Paola Manara, Yitzhar E. Goretsky, David M. Suissa, Marco Vincenzo Russo, Nikolai Fattakhov, David Carmona-Berrio, Natalia Campos Gallego, Caroline A. Coughlin, Anya K. Sondhi, Evan R. Roberts, Jay Y. Spiegel, Juan Pablo Alderuccio, Catalina Amador, Daniel Bilbao, David G. Coffey, Michael D. Jain, Francesco Maura, Frederick L. Locke, Jonathan H. Schatz

    Erschienen: 2026-11-03DOI: 10.1158/2643-3230.bcd-25-0482

  3. Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma

    Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, Lorenzo Falchi, Qi Gao, Gregory Goldgof, Marina Gomez-Llobell, Erel Joffe, Richard J. Lin, Alejandro Luna de Abia, Efrat Luttwak, M. Lia Palomba, Jae H. Park, Sandeep S. Raj, Kai Rejeski, Alfredo Rivas-Delgado, Gilles Salles, Jaime Sanz, Michael Scordo, Gunjan L. Shah, Sulov Chalise, Manik Uppal, Anna Gurevich-Shapiro, Menglei Zhu, Miguel-Angel Perales, Allison L. Richards, Mikhail Roshal, Roni Shouval

    Erschienen: 2026-11-03DOI: 10.1158/2643-3230.bcd-25-0501

  4. Spatial Profiling Identifies a Distinct and Topographically Defined Tumor Microenvironment that Emerges during Multiple Myeloma Evolution

    Marnix Koops, Luca Bertamini, Natalie Papazian, Charlotte Korst, Mátyás János Budai, Remco M. Hoogenboezem, Mathijs A. Sanders, Bronno van der Holt, Mark van Duin, Annemiek Broijl, Péter Balogh, Sonja Zweegman, Marc H.G.P. Raaijmakers, Niels W.C.J. van de Donk, Zoltán Kellermayer, Pieter Sonneveld, Tom Cupedo

    Erschienen: 2026-11-03DOI: 10.1158/2643-3230.bcd-26-0080

  5. Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study

    Ruixian Xing, Apeng Yang, Juan Huang, Liang Wang, Wei Guo, Qu Cui, Xiaoqiong Tang, Yuanyuan Ma, Kai Hu, Tianheng He, Danyang Wu, Xiaofang Deng, Yajing Zhang, Kaili Zhong, Yang Liu, Yixian Guo, Ying Wang, Chan Long, Chongyang Wu, Xin Lu, Fengmin Li, Jiefei Bai, Jun Qian, Xuefei Sun, Wenrong Huang, Hui Zhou, Huilai Zhang, Ou Bai, Xiaobing Huang, Zhiyong Zeng, Lin Fu

    Erschienen: 2026-11-03DOI: 10.1158/2643-3230.bcd-26-0128

  6. Prophylactic IFN-γ blockade drives axi-cel expansion without preventing refractory toxicities: caution against pre-emptive use

    Viktoria Blumenberg, David J. Bozym, Maxx King, Marisa G. Ogier, Deshea L. Harris, Keshav Sridharan, Jing Li, Patrick C. Johnson, Benjamin R. Puliafito, Alexandra M. Haugh, Jacob D. Soumerai, Julie E. Haydu, Elliot C. Woods, Jeremy S. Abramson, Yi-Bin Chen, Mark B. Leick, Kathleen ME. Gallagher, Marcela V. Maus, Matthew J. Frigault

    Erschienen: 2026-10-19DOI: 10.1158/2643-3230.bcd-26-0249

  7. A phase 1, first-in-human study of safimaltib, a MALT1 inhibitor, in B-lymphocytic malignancies

    Mark Hertzberg, Chan Y. Cheah, Stephen Opat, Matko Kalac, Pau Abrisqueta, Vincent Ribrag, Emmanuel Bachy, Loïc Ysebaert, Lugui Qiu, Erel Joffe, Shuhua Yi, Pier Luigi Zinzani, Alessandra Tedeschi, Noriko Nishimura, Charlotte R. Lemech, Jacqueline Bussolari, Changchun Deng, Alemu Takele Assefa, Sandy Van Hemelryck, Jan Snoeys, Brendan P. Hodkinson, Nele Fourneau, Yu Cao, Srimathi Srinivasan, Yue Guo, Virginie Soete, Isabel Soriano Paradinas, Lorena Fontan, Ulrike Philippar, John F. Gerecitano, Franck Morschhauser

    Erschienen: 2026-09-30DOI: 10.1158/2643-3230.bcd-26-0179

  8. Very Long Chain Fatty Acid Synthesis is a Targetable Dependency in RAS Pathway Mutant Leukemia

    Rebecca Gelfer, Maya Bagish, Merve Sahin, Kaitlyn H. Ko, Maria Sirenko, Matthew Wereski, Gabriel San Miguel-Matos, Angelica C. Romero-Vega, Shoron Mowla, Nathaniel B. Long, Michelle Saoi, Clementina Strozek, Su-Fern Tan, Christopher A. Famulare, Kevin Chen, B. Bishal Paudel, Madhuri Madavaram, Zhuoning Li, Michael R. Waarts, Xiaodi Wu, Justin R. Cross, Wenbin Xiao, Iannis Aifantis, Tak Wah. Mak, Todd E. Fox, David J. Feith, Elisa de Stanchina, Mara Monetti, Richard P. Koche, Sheng F. Cai, Ross L. Levine

    Erschienen: 2026-09-30DOI: 10.1158/2643-3230.bcd-26-0274

  9. A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL

    Michaela Su-fern Seng, Zexi Guo, Kai Soon Ng, Shui Yen Soh, Francesca Wei Inng Lim, Liang Piu Koh, William YK. Hwang, Aloysius YL. Ho, Yeh Ching Linn, Esther Hian Li Chan, Michelle L.M. Poon, Lip Kun Tan, Mickey BC. Koh, Tun Kiat Ko, Jia Yu, King Pan Ng, Teck Guan Soh, Jason Yongsheng Chan, Joe Poh Sheng. Yeong, Rimas J. Orentas, Wing Leung

    Erschienen: 2026-09-21DOI: 10.1158/2643-3230.bcd-26-0115

  10. Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry

    Kylee H. Maclachlan, Marios Papadimitriou, Patrick Blaney, Linda B. Baughn, Tala Shekarkhand, Alexandra M. Poos, Bachisio Ziccheddu, Hongwei Tang, Huihuang Yan, Benjamin Diamond, Yanming Zhang, Robert Cimera, Ahmet Dogan, Dylan Gagler, Eileen Boyle, Malin Hultcrantz, Sham Mailankody, Hani Hassoun, Urvi A. Shah, Carlyn Tan, Elizabeth E. Brown, Lara Winterkorn, Timothy Chu, Zoe Steinsnyder, Zalman Vaksman, Faith E. Davies, Neha Korde, Ola Landgren, Marc S. Raab, Alexander M. Lesokhin, Nicolas Robine, Niels Weinhold, Saad Z. Usmani, Francesco Maura, Gareth J. Morgan

    Erschienen: 2026-09-03DOI: 10.1158/2643-3230.bcd-25-0259

  11. LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models

    Nathan A. Brooks, Anna Skwarska, Vivian Salama, Mark H. Bender, Lisa Kays, Robin I. DeWalt, Bryan Perria, Deepti Thete, Jason R. Manro, Rachel Cavitt, Rebecca Leon, Sandra Gomez, Raquel Torres, John M. Strelow, Paul Milligan, Kate Newell, Kenneth D. Roth, Jean-Emmanuel Sarry, Steven M. Chan, Danalyn Manglicmot Lagutan, Richard Romero, Stephen Antonysamy, Robert L. Johnson, Xueqian Gong, Renato A. Bauer, Timothy P. Burkholder, Patric J. Hahn, Zoran Rankovic, Serge L. Boulet, Courtney D. DiNardo, Marina Konopleva, Raymond Gilmour

    Erschienen: 2026-09-03DOI: 10.1158/2643-3230.bcd-25-0379

  12. Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma

    Maximilian Merz, Tomas Jelinek, Thomas Pabst, Raphael Teipel, Anca-Maria Albici, Bastian von Tresckow, Marcel Teichert, Uta Margareta Demel, Antonia Busse, Marie Christine Wesener, Tobias A.W. Holderried, Friederike Schmitz, Friedrich-Linus Rößiger, Fabian Müller, Michele Hoffmann, Friedrich Stölzel, Natalia Tovar, Ben-Niklas Baermann, Martin Stork, Alexandra Jungova, Jiri Minarik, Jakub Radocha, Ivan Spicka, Ludek Pour, Polona Novak, Klara Slajpah, Karla Rener, Ulrich Keller, Stephan Bohl, David Fandrei, Patrick Born, Vladan Vučinić, Nicolaus Kröger, Irene Strassl, Natalie Schub, Roman Hájek, Matjaž Sever, Carlos Fernández de Larrea, Nico Gagelmann

    Erschienen: 2026-09-03DOI: 10.1158/2643-3230.bcd-25-0461

  13. The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells

    Sweta B. Patel, Daniel R. Moskop, Steven Moreira, Stephanie Gipson, Colin C. Anderson, Alexandra Crook, Maxwell McCabe, Daniel Stephenson, Hannah E. Terry, Andrew Kent, Tracy N. Young, Anna E. Krug, Connon I. Thomas, Caitlin Price, Monica Ransom, Regan Miller, Ana Vujovic, Mohammad Minhajuddin, Mark J. Althoff, Anthony J. Saviola, Brett M. Stevens, Robert S. Welner, Ekaterina L. Andrianova, Andrei V. Gudkov, Anza Darehshouri, Julie A. Reisz, Travis Nemkov, Angelo D’Alessandro, Austin E. Gillen, Daniel A. Pollyea, Craig T. Jordan, Eric M. Pietras

    Erschienen: 2026-09-03DOI: 10.1158/2643-3230.bcd-25-0498

  14. A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma

    Haopeng Yang, Kotaro Arita, Kevin Bowman, Dai Chihara, Jared Henderson, Griffin Rost, Estela Rojas, Sydney Parsons, Priya Lakra, Aneela Syeda Abedin, Sattva S. Neelapu, Paolo Strati, Loretta J. Nastoupil, Luis E. Fayad, Swaminathan P. Iyer, Maria Alma Rodriguez, Fredrick B. Hagemeister, Luis Malpica, Hun Lee, Laura K. Hilton, David W. Scott, R. Eric Davis, Christopher R. Flowers, Jason R. Westin, Giorgio Inghirami, Francisco Vega, Michael R. Green

    Erschienen: 2026-09-03DOI: 10.1158/2643-3230.bcd-26-0005

Jahrgänge

2026 · 792025 · 592024 · 462023 · 492022 · 542021 · 642020 · 116

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.